德視佳(01846.HK)預計年度純利達1.32億至1.38億港元
格隆匯1月13日丨德視佳(01846.HK)發佈公吿,公司預計截至2021年12月31日止年度將錄得公司擁有人應占溢利1.32億港元至1.38億港元,而截至2020年12月31日止年度則為6560萬港元。
董事會認為,相較於去年度,集團於該年度的財務業績及表現有所好轉主要歸因於(i)對後房型人工晶體(ICL)植入術及三焦點晶體置換手術的需求增加;(ii)於2021年下半年後,眼科手術數量保持強勁並持續增長;及(iii)COVID-19疫情對集團整體業務的影響已得到控制的綜合影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.